EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor

Seth A Reasoner iD, Rachel Bernard iD, Adam Waalkes iD, Kelsi Penewit iD, Janessa Lewis, Andrew G Sokolow iD, Rebekah F Brown iD, Kathryn M Edwards iD, Stephen J Salipante iD, Maria Hadjifrangiskou iD, Maribeth R Nicholson iD

mBio · 2024

DOI: 10.1128/mbio.01935-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Seth A Reasoner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, Division of Molecular Pathogenesis, Vanderbilt University Medical Center, Nashville, Tennessee…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Gastrointestinal Microbiome, Benzodioxoles, Indoles. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is an autosomal recessive disease with significant gastrointestinal symptoms in addition to pulmonary complications. Recently approved treatments for CF, CF transmembrane conductance regulator (CFTR) modulators, are anticipated to substantially improve the care of people with CF and extend their lifespans. Prior work has shown that the intestinal microbiome correlates with health outcomes in CF, particularly in children. Here, we study the intestinal microbiome of children with CF before and after the CFTR modulator, ELX/TEZ/IVA. We identify promising improvements in microbiome diversity, reduced measures of intestinal inflammation, and reduced antibiotic resistance genes. We present specific bacterial taxa and protein groups which change following ELX/TEZ/IVA. These results will inform future mechanistic studies to understand the microbial improvements associated with CFTR modulator treatment. This study demonstrates how the microbiome can change in response to a targeted medication that corrects a genetic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisGastrointestinal MicrobiomeBenzodioxolesIndolesAminophenolsPyrazolesPyridinesPyrrolidinesQuinolonesChildHumansCystic Fibrosis Transmembrane Conductance RegulatorAnti-Bacterial AgentsInflammationMutation

Stichwörter der Autor:innen

CFTR modulatorantibiotic resistancecystic fibrosiselexacaftorintestinal inflammationivacaftormetagenomic sequencingmicrobiomepediatrictezacaftor

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorelexacaftorivacaftortezacaftorAnti-Bacterial AgentsBenzodioxolesIndolesAminophenolsPyrazolesPyridines

Autor:innen und Institutionen

  • Department of Pathology, Microbiology, and Immunology, Division of Molecular Pathogenesis, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Department of Pediatrics, Division of Allergy, Immunology, and Pulmonary Medicine, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
  • Department of Pediatrics, Division of Infectious Diseases, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
  • Center for Personalized Microbiology (CPMi), Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Seth A Reasoner, Rachel Bernard, Adam Waalkes, Kelsi Penewit, Andrew G Sokolow, Rebekah F Brown, Kathryn M Edwards, Stephen J Salipante, Maria Hadjifrangiskou, Maribeth R Nicholson

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
  • HHS | NIH | National Institute of General Medical Sciences
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • Thrasher Research Fund
  • Cystic Fibrosis Foundation

Zitieren

APA

Reasoner, S. A., Bernard, R., Waalkes, A., Penewit, K., Lewis, J., Sokolow, A. G., Brown, R. F., Edwards, K. M., Salipante, S. J., Hadjifrangiskou, M., & Nicholson, M. R. (2024). Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor. mBio. https://doi.org/10.1128/mbio.01935-23

Vancouver

Reasoner SA, Bernard R, Waalkes A, Penewit K, Lewis J, Sokolow AG, et al. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor. mBio. 2024. doi:10.1128/mbio.01935-23

BibTeX
@article{Reasoner2024,
  author = {Reasoner, Seth A and Bernard, Rachel and Waalkes, Adam and Penewit, Kelsi and Lewis, Janessa and Sokolow, Andrew G and Brown, Rebekah F and Edwards, Kathryn M and Salipante, Stephen J and Hadjifrangiskou, Maria and Nicholson, Maribeth R},
  title = {Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.01935-23}
}
Kostenlos starten →